BioSpace News Archive

IGM Biosciences, Inc. (NASDAQ: IGMS) today announced the closing of its previously announced upsized underwritten public offering of 1,597,827 shares of its voting common stock and 9,000,000 shares of its non-voting common stock and including the full exercise of the underwriters’ option to purchase 1,589,673 shares of its voting common stock, at a public offering price of $8.00 per share.

ImmunoGen, Inc. announced that the compensation committee of the Company’s Board of Directors approved, effective as of June 30, 2023, grants of non-qualified stock options to purchase 32,300 shares of its common stock and restricted stock units covering 16,150 shares of its common stock under the Inducement Plan to three new employees.

Agile Therapeutics announced the closing of its public offering in May. The women’s healthcare company raised $7.5 million in gross proceeds after selling over 1.8 million shares of common stock at $3.95 per share.

The New York Stock Exchange announced that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of SQZ Biotechnologies Company — ticker symbol SQZ — from the NYSE.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Company’s New Drug Application (NDA) for IPX203 for the treatment of Parkinson’s disease.

Acutus Medical, Inc. granted equity awards on July 1, 2023 that were approved by the Compensation Committee of its Board of Directors under Company’s 2022 Inducement Equity Incentive Plan, as a material inducement to employment to 3 individuals hired by Acutus in June 2023.

Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release second quarter 2023 financial results on Thursday, July 27, 2023, prior to the market open.

Olympus Corporation has announced a voluntary field corrective action to address complaints of endobronchial combustion occurring when laser-compatible bronchoscopes are used during therapeutic procedures in combination with laser therapy equipment or argon plasma coagulation.

Trinity Biotech plc, a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the first quarter fiscal year 2023 on Thursday, July 6, 2023.

NLS Pharmaceutics Ltd. today announced that the U.S. Food and Drug Administration (FDA) has reviewed the full protocol for the NLS-1031 study, part of the Phase 3 program for Mazindol ER, called AMAZE.